265 related articles for article (PubMed ID: 23943614)
1. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view.
Hu S; Liang S; Guo H; Zhang D; Li H; Wang X; Yang W; Qian W; Hou S; Wang H; Guo Y; Lou Z
J Biol Chem; 2013 Sep; 288(38):27059-27067. PubMed ID: 23943614
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab.
Liang S; Dai J; Hou S; Su L; Zhang D; Guo H; Hu S; Wang H; Rao Z; Guo Y; Lou Z
J Biol Chem; 2013 May; 288(19):13799-807. PubMed ID: 23504311
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
5. [Development and Optimization of Therapeutic Analogues of Anti-TNFα Antibody Infliximab].
Yu XJ; Shen YF; Dong J; Li T; Wang C; Zhang YJ; Wang LF; Meng YC; Yang Y; Wang HJ; Lei CH; Hu S; Li BH
Mol Biol (Mosk); 2018; 52(4):628-633. PubMed ID: 30113028
[TBL] [Abstract][Full Text] [Related]
6. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
Bourne T; Fossati G; Nesbitt A
BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
8. Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases.
Lee JU; Shin W; Son JY; Yoo KY; Heo YS
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28124979
[TBL] [Abstract][Full Text] [Related]
9. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
Tan E; Baker C; Foley P
Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
Alonso-Ruiz A; Pijoan JI; Ansuategui E; Urkaregi A; Calabozo M; Quintana A
BMC Musculoskelet Disord; 2008 Apr; 9():52. PubMed ID: 18419803
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison.
Wang Y; Wang H; Jiang J; Zhao D; Liu Y
Cell Physiol Biochem; 2016; 39(5):1679-1694. PubMed ID: 27643888
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
13. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
14. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
Benucci M; Saviola G; Baiardi P; Cammelli E; Manfredi M
Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
[TBL] [Abstract][Full Text] [Related]
15. TNFalpha blockade in human diseases: mechanisms and future directions.
Wong M; Ziring D; Korin Y; Desai S; Kim S; Lin J; Gjertson D; Braun J; Reed E; Singh RR
Clin Immunol; 2008 Feb; 126(2):121-36. PubMed ID: 17916444
[TBL] [Abstract][Full Text] [Related]
16. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical effects of anti-TNFalpha treatment.
Valesini G; Iannuccelli C; Marocchi E; Pascoli L; Scalzi V; Di Franco M
Autoimmun Rev; 2007 Nov; 7(1):35-41. PubMed ID: 17967723
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases.
Caramaschi P; Bambara LM; Pieropan S; Tinazzi I; Volpe A; Biasi D
Joint Bone Spine; 2009 Jul; 76(4):333-42. PubMed ID: 19539516
[TBL] [Abstract][Full Text] [Related]
19. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
20. New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis.
Meroni PL; Valentini G; Ayala F; Cattaneo A; Valesini G
Autoimmun Rev; 2015 Sep; 14(9):812-29. PubMed ID: 25985765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
